Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | FASN | P49327 | 2/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23770773 | 0.87 | ABL1 (0.37) | S1PR1ABL1 | |
| SCHEMBL23770430 | 0.86 | ABL1 (0.33) | CDC7CDK2KCNH2MAP3K14ABL1 | |
| SCHEMBL23770607 | 0.84 | JAK2 (0.35) | CDK2FASNABL1 | |
| SCHEMBL23770652 | 0.82 | HSD11B1 (0.32) | PTGDR2CDC7CDK2 | |
| SCHEMBL23770543 | 0.80 | S1PR1 (0.35) | S1PR1SYK | |
| SCHEMBL19927777 | 0.80 | SCN9A (0.43) | — | |
| SCHEMBL29464436 | 0.80 | SCN9A (0.43) | — | |
| SCHEMBL23770666 | 0.77 | KRAS (0.39) | PTGDR2FASNEGLN2 | |
| SCHEMBL23770732 | 0.76 | NOS3 (0.38) | S1PR1SYKABL1 | |
| SCHEMBL23770776 | 0.73 | ABL1 (0.38) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |